---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-024067"
form_type: "8-K"
ticker: "VIR"
cik: "0001706431"
company_name: "Vir Biotechnology, Inc."
filed_at: "2025-05-09T23:59:59+00:00"
generated_at: "2026-05-22T01:51:55.862025+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Vir Biotech reports HBsAg loss in MARCH study but halts Phase 3 for chronic HBV without partner

## Summary
- HBsAg loss 24 weeks post-treatment: 17% (3/18) and 21% (3/14) in low baseline HBsAg patients with tobevibart+elebsiran without/with PEG-IFNα.
- No global development partner secured for chronic HBV; Phase 3 will not proceed.
- Company to streamline final stages of MARCH Phase 2, focusing on hepatitis delta ECLIPSE Phase 3 and T-cell engager oncology programs.
- Cash runway guidance into mid-2027 reaffirmed based on current operating plan.
- Safety profile consistent; no new concerns; generally mild/moderate adverse events.

## SEC filing metadata
- accession: 0001628280-25-024067
- form_type: 8-K
- ticker: VIR
- cik: 0001706431
- company_name: Vir Biotechnology, Inc.
- filed_at: 2025-05-09T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1706431/000162828025024067/0001628280-25-024067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1706431/000162828025024067/vir-20250509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-024067
- JSON: https://secwatch.observer/filing/0001628280-25-024067.json
- Plain text: https://secwatch.observer/filing/0001628280-25-024067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.